메뉴 건너뛰기




Volumn 227, Issue 4, 2014, Pages 305-310

Golimumab in patients affected by moderate to severe psoriatic arthritis: An open-label study in thirty-two patients previously treated with other biologics

Author keywords

Golimumab; Monotherapy; Psoriasis; Psoriatic arthritis

Indexed keywords

ADALIMUMAB; ANTIINFECTIVE AGENT; CYCLOSPORIN; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

EID: 84892184923     PISSN: 10188665     EISSN: 14219832     Source Type: Journal    
DOI: 10.1159/000354263     Document Type: Article
Times cited : (10)

References (24)
  • 1
    • 0038025436 scopus 로고    scopus 로고
    • The role of T cells in psoriasis
    • Prinz J: The role of T cells in psoriasis. J Eur Acad Dermatol Venereol 2003; 17: 257-270.
    • (2003) J Eur Acad Dermatol Venereol , vol.17 , pp. 257-270
    • Prinz, J.1
  • 2
    • 0035724176 scopus 로고    scopus 로고
    • Psoriasis-epidemiology and clinical spectrum
    • review
    • Christophers E: Psoriasis-epidemiology and clinical spectrum. Clin Exp Dermatol 2001; 26: 314-320, review.
    • (2001) Clin Exp Dermatol , vol.26 , pp. 314-320
    • Christophers, E.1
  • 3
    • 0345099477 scopus 로고    scopus 로고
    • A prospective, clinical and radiological study of early psoriatic arthritis: An early synovitis clinic experience
    • Kane D, Stafford L, Bresnihan B, FitzGerald O: A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology (Oxford) 2003; 42: 1460-1468.
    • (2003) Rheumatology (Oxford) , vol.42 , pp. 1460-1468
    • Kane, D.1    Stafford, L.2    Bresnihan, B.3    Fitzgerald, O.4
  • 4
    • 33847279025 scopus 로고    scopus 로고
    • Pathogenesis and therapy of psoriasis
    • Lowes MA, Bowcock AM, Krueger JG: Pathogenesis and therapy of psoriasis. Nature 2007; 445: 866-873.
    • (2007) Nature , vol.445 , pp. 866-873
    • Lowes, M.A.1    Bowcock, A.M.2    Krueger, J.G.3
  • 6
    • 33746951437 scopus 로고    scopus 로고
    • Classification criteria for psoriatic arthritis: Development of new criteria from a large international study
    • CASPAR Study Group
    • Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, CASPAR Study Group: Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006; 54: 2665-2673.
    • (2006) Arthritis Rheum , vol.54 , pp. 2665-2673
    • Taylor, W.1    Gladman, D.2    Helliwell, P.3    Marchesoni, A.4    Mease, P.5    Mielants, H.6
  • 10
    • 84875211531 scopus 로고    scopus 로고
    • Efficacy and safety of subcutaneous anti-tumor necrosis factoralpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: An observational longterm study
    • Esposito M, Giunta A, Mazzotta A, Zangrilli A, Babino G, Bavetta M, Perricone R, Chimenti S, Chimenti MS: Efficacy and safety of subcutaneous anti-tumor necrosis factoralpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational longterm study. Dermatology 2012; 225: 312-319.
    • (2012) Dermatology , vol.225 , pp. 312-319
    • Esposito, M.1    Giunta, A.2    Mazzotta, A.3    Zangrilli, A.4    Babino, G.5    Bavetta, M.6    Perricone, R.7    Chimenti, S.8    Chimenti, M.S.9
  • 11
    • 84877053271 scopus 로고    scopus 로고
    • Etanercept provides an effective, safe and flexible short-and long-term treatment regimen for moderate-to-severe psoriasis: A systematic review of current evidence
    • Strohal R, Chimenti S, Vena GA, Girolomoni G: Etanercept provides an effective, safe and flexible short-and long-term treatment regimen for moderate-to-severe psoriasis: a systematic review of current evidence. J Dermatolog Treat 2012; 24: 199-208.
    • (2012) J Dermatolog Treat , vol.24 , pp. 199-208
    • Strohal, R.1    Chimenti, S.2    Vena, G.A.3    Girolomoni, G.4
  • 14
    • 84864401979 scopus 로고    scopus 로고
    • Treatment of psoriatic arthritis with tumor necrosis factor inhibitors: Longer-term outcomes including enthesitis and dactylitis with golimumab treatment in the Longterm Extension of a Randomized, Placebo-controlled Study (GOREVEAL)
    • Kavanaugh A, Mease P: Treatment of psoriatic arthritis with tumor necrosis factor inhibitors: longer-term outcomes including enthesitis and dactylitis with golimumab treatment in the Longterm Extension of a Randomized, Placebo-controlled Study (GOREVEAL). J Rheumatol Suppl 2012; 89: 90-93.
    • (2012) J Rheumatol Suppl , vol.89 , pp. 90-93
    • Kavanaugh, A.1    Mease, P.2
  • 16
    • 84857238069 scopus 로고    scopus 로고
    • A systematic literature review of drug therapies for the treatment of psoriatic arthritis: Current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis
    • Ash Z, Gaujoux-Viala C, Gossec L, Hensor EM, FitzGerald O, Winthrop K, van der Heijde D, Emery P, Smolen JS, Marzo-Ortega H: A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis 2012; 71: 319-326.
    • (2012) Ann Rheum Dis , vol.71 , pp. 319-326
    • Ash, Z.1    Gaujoux-Viala, C.2    Gossec, L.3    Hensor, E.M.4    Fitzgerald, O.5    Winthrop, K.6    Van Der Heijde, D.7    Emery, P.8    Smolen, J.S.9    Marzo-Ortega, H.10
  • 18
    • 33745080328 scopus 로고    scopus 로고
    • Development of classification and response criteria for rheumatic diseases
    • Classification and Response Criteria Subcommittee of the Committee on Quality Measures, American College of Rheumatology
    • Singh J A, Solomon D H, Dougados M, Felson D, Hawker G, Katz P, Paulus H, Wallace C, Classification and Response Criteria Subcommittee of the Committee on Quality Measures, American College of Rheumatology: Development of classification and response criteria for rheumatic diseases. Arthritis Rheum 2006; 55: 348-352.
    • (2006) Arthritis Rheum , vol.55 , pp. 348-352
    • Singh, J.A.1    Solomon, D.H.2    Dougados, M.3    Felson, D.4    Hawker, G.5    Katz, P.6    Paulus, H.7    Wallace, C.8
  • 21
    • 80051670470 scopus 로고    scopus 로고
    • Anti-TNF? Discontinuation in rheumatoid and psoriatic arthritis: Is it possible after disease remission?
    • Chimenti MS, Graceffa D, Perricone R: Anti-TNF? discontinuation in rheumatoid and psoriatic arthritis: is it possible after disease remission? Autoimmun Rev 2011; 10: 636-640
    • (2011) Autoimmun Rev , vol.10 , pp. 636-640
    • Chimenti, M.S.1    Graceffa, D.2    Perricone, R.3
  • 22
    • 84883577100 scopus 로고    scopus 로고
    • The first decade of biologic TNF antagonists in clinical practice: Lessons learned, unresolved issues and future directions
    • Sfikakis PP: The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions. Curr Dir Autoimmun 2010; 11: 180-210.
    • (2010) Curr Dir Autoimmun , vol.11 , pp. 180-210
    • Sfikakis, P.P.1
  • 23
    • 65449189497 scopus 로고    scopus 로고
    • Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: Observational study from the British Society of Rheumatology Biologics Register
    • British Society for Rheumatology Biologics Register
    • Saad AA, Ashcroft DM, Watson KD, Hyrich KL, Noyce PR, Symmons DP, British Society for Rheumatology Biologics Register: Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register. Arthritis Res Ther 2009; 11:R52.
    • (2009) Arthritis Res Ther , vol.11
    • Saad, A.A.1    Ashcroft, D.M.2    Watson, K.D.3    Hyrich, K.L.4    Noyce, P.R.5    Symmons, D.P.6
  • 24
    • 79951691645 scopus 로고    scopus 로고
    • Changes in disease characteristics and response rates among patients in the United Kingdom starting antitumour necrosis factor therapy for rheumatoid arthritis between 2001 and 2008
    • British Society for Rheumatology Biologics Register (BSRBR)
    • Hyrich KL, Watson KD, Lunt M, Symmons DP, British Society for Rheumatology Biologics Register (BSRBR): Changes in disease characteristics and response rates among patients in the United Kingdom starting antitumour necrosis factor therapy for rheumatoid arthritis between 2001 and 2008. Rheumatology (Oxford) 2011; 50: 117-123.
    • (2011) Rheumatology (Oxford) , vol.50 , pp. 117-123
    • Hyrich, K.L.1    Watson, K.D.2    Lunt, M.3    Symmons, D.P.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.